Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patient Feedback Pioneers: Chronic Fatigue Advocates Prepare for First PDUFA V Meeting

This article was originally published in RPM Report

Executive Summary

FDA has selected CFS/ME as the first topic for the PDUFA V patient-centered drug development initiative. The lessons learned from this session will inform future work on patient engagement in drug development both for FDA—and for patient advocates.

You may also be interested in...



ALS Association Drafting Drug Development Guidance; Learning From DMD Advocacy

A Lou Gehrig’s disease patient advocacy group is moving forward with a drug development guidance of its own to the jumpstart the regulatory approval process.

PhRMA Wades Into FDA Patient-Focused Data Collection: Website Systems for Crowd-Sourced Info

Trade association partners with Genetic Alliance to provide input into FDA drug development initiative. That may be an effective intervention by PhRMA as it experiments with new ways to shape regulatory policy beyond traditional advocacy efforts.

Confluence of Symptoms and Treatments at FDA Patient Meetings

The first round of four PDUFA patient-focused meetings concluded with the Sept. 24 meeting on narcolepsy. FDA is beginning to look ahead to the fiscal 2014 meetings – to start with fibromyalgia on December 10. One pattern that is emerging is that three of the first five conditions discussed with patients have overlapping symptoms and treatments.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS081125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel